Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Immuron ( (IMRN) ) has issued an announcement.
On November 6, 2025, Immuron Limited announced a proposed issue of 8,495,080 ordinary fully paid securities as part of a placement. The issue, priced at AUD 0.07560 per security, aims to fund further research and development activities and provide ongoing working capital. The shares were purchased by US investors through the company’s US At-The-Market facility, managed by H.C. Wainwright & Co. This strategic move is expected to bolster Immuron’s financial resources, enhancing its capacity to advance its R&D initiatives and maintain operational stability.
The most recent analyst rating on (IMRN) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Immuron stock, see the IMRN Stock Forecast page.
Spark’s Take on IMRN Stock
According to Spark, TipRanks’ AI Analyst, IMRN is a Underperform.
Immuron’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. The technical analysis indicates a bearish trend, with the stock being oversold. Valuation metrics further highlight the company’s financial struggles, with a negative P/E ratio. The lack of earnings call data and corporate events means these components do not influence the score.
To see Spark’s full report on IMRN stock, click here.
More about Immuron
Immuron Limited is a company based in Australia, operating in the biotechnology industry. It focuses on the development and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases.
Average Trading Volume: 165,520
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.67M
For detailed information about IMRN stock, go to TipRanks’ Stock Analysis page.